
OCT 3 1 2003



Worldwide Medicines Group
P.O. Box 4000 Princeton, NJ 08543-4000 Tel: 609 252-5914; Fax: 609 252-4526

Date October 30, 2003

FACSIMILE TRANSMITTAL SHEET

TO: Examiner Vickey Kim
FACSIMILE NO: 703-746-3165
TELEPHONE NO: _ 703-305-1675
FROM:Jing Belfield
TELEPHONE NO: 609-252-3791
COMPANY: Bristol-Myers Squibb Company
FACSIMILE NO:609-252 -4526
TOTAL NUMBER OF PAGES INCLUDING THIS COVER PAGE: /3
If you do not receive a complete fax please contact Hilda Franco at 609-252-5914
Re: Docket No. PH7038; USSN 09/519,188; Filed; March 6, 2000; Wong, et al.
As discussed enclosed is the Amendment and Request for Reconsideration dated

OCT.30.2003 6:27PN

609 252 4526

NO.916

P.3

Docket No.: PH-7038 USSN: 09/519,188

	Docket Number	PH-7038	
FILING BY "EXPRESS N	RECEIVED		
EV323500379US Express Mail Label Number		July 29, 2003 Date of Deposit	CENTRAL FAX CENTER OCT 3 1 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appln. of: Wong) U.S. Serial No.: 09/519,188
Filed:	03/06/2000) Examiner: Kim, V.) Art Unit: 1614
For:	Treatment of Thrombosis by Combined Use of a Factor Xa Inhibitor and Aspirin, Tissue Plasminogen Activator (TPA) a GPIIb/IIIa Antagonist, Low Molecular Weight Heparin or Heparin)))))

Hon. Assistant Commissioner for Patents

Washington, D.C. 20231

Date: July 29, 2003

Dear Sir:

AMENDMENT AND REQUEST FOR RECONSIDERATION

Responsive to the Office Action dated April 3, 2003, Applicant respectfully requests reconsideration in view of the following amendment and remarks.